An AI-powered penetration testing tool is automating offensive cybersecurity, accelerating vulnerability discovery and ...

The annual Florida Python Challenge was held in July this year and when all of the counting was completed, a woman from ...

Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

The latest trends and issues around the use of open source software in the enterprise. JetBrains has detailed its eighth annual Python Developers Survey. This survey is conducted as a collaborative ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...